Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27323536 | 0.78 | SIGMAR1 (0.59) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL8380136 | 0.76 | SIGMAR1 (0.57) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL2452523 | 0.76 | SIGMAR1 (0.57) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL7499611 | 0.75 | SIGMAR1 (0.55) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL9690053 | 0.74 | MEN1 (0.48) | SIGMAR1LMNAACHECYP3A4MEN1 | |
| SCHEMBL4506489 | 0.74 | SIGMAR1 (0.53) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL5763310 | 0.73 | CCR3 (0.55) | SIGMAR1HRH3MC4RCCR3KMT2A | |
| SCHEMBL11884735 | 0.73 | SIGMAR1 (0.52) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL4772258 | 0.73 | SIGMAR1 (0.61) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL7380692 | 0.72 | SIGMAR1 (0.55) | SIGMAR1HRH3MC4RDRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | SIGMAR1 1579/4885HRH3 12/4885MC4R 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.